Sarah Burgess Reed - 08 Sep 2025 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role: Director
Signature: /s/ Sherell Bacchas, Attorney-in-Fact
Issuer symbol: VOR
Transactions as of: 08 Sep 2025
Net transactions value: $0
Form type: 4
Filing time: 10 Sep 2025, 16:10:05 UTC
Previous filing: 08 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Reed Sarah Burgess	Director	C/O VOR BIOPHARMA INC., 500 BOYLSTON STREET, SUITE 1350, BOSTON	/s/ Sherell Bacchas, Attorney-in-Fact	10 Sep 2025	0002085062

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VOR	Stock Option (Right to Buy)	Award	$0	+60,000		$0.000000	60,000	08 Sep 2025	Common Stock	60,000	$1.98	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on September 8, 2025, in each case subject to the Reporting Person's continued service as of each such date.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on September 8, 2025, in each case subject to the Reporting Person's continued service as of each such date.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.